Fresenius Kabi Gets Ready To Launch Europe’s First Tocilizumab Rival
Biosimilar Version Of RoActemra Receives Formal European Commission Approval
Fresenius Kabi has celebrated the approval of Europe’s first tocilizumab biosimilar. The rival to RoActemra is expected to be launched later this year under a settlement agreement with originator Genentech.
